The emerging landscape of immune cell therapies
Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …
immune cell therapies are among the most advanced, having already demonstrated …
Heterogeneity of the tumor immune microenvironment and its clinical relevance
Q Jia, A Wang, Y Yuan, B Zhu, H Long - Experimental hematology & …, 2022 - Springer
During the course of tumorigenesis and subsequent metastasis, malignant cells gradually
diversify and become more heterogeneous. Consequently, the tumor mass might be …
diversify and become more heterogeneous. Consequently, the tumor mass might be …
Tuning the antigen density requirement for CAR T-cell activity
Insufficient reactivity against cells with low antigen density has emerged as an important
cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that …
cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that …
Bispecific antibodies and antibody–drug conjugates for cancer therapy: technological considerations
H Shim - Biomolecules, 2020 - mdpi.com
The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or
stimulate its activity is the basis for the rapid growth and development of the therapeutic …
stimulate its activity is the basis for the rapid growth and development of the therapeutic …
In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
T **n, L Cheng, C Zhou, Y Zhao, Z Hu, X Wu - Frontiers in oncology, 2022 - frontiersin.org
Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the
treatment of hematological malignancies, but the systemic toxicity and complex …
treatment of hematological malignancies, but the systemic toxicity and complex …
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations
of novel constructs being developed at a rapid pace. Since the initial reports of chimeric …
of novel constructs being developed at a rapid pace. Since the initial reports of chimeric …
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Abstract Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen
(BCMA) mediate profound responses in patients with multiple myeloma, but most patients do …
(BCMA) mediate profound responses in patients with multiple myeloma, but most patients do …
Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-
targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target …
targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target …
Multispecific CAR T cells deprive lymphomas of escape via antigen loss
Chimeric antigen receptor (CAR) modified T cell therapy has transformed the management
of relapsed/refractory B cell malignancies. Despite high overall response rates, relapse post …
of relapsed/refractory B cell malignancies. Despite high overall response rates, relapse post …
CAR T cells and T-cell therapies for cancer: A translational science review
JN Brudno, MV Maus, CS Hinrichs - Jama, 2024 - jamanetwork.com
Importance Chimeric antigen receptor (CAR) T cells are T lymphocytes that are genetically
engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and …
engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and …